196 related articles for article (PubMed ID: 7768627)
1. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.
Mallett CP; Hale TL; Kaminski RW; Larsen T; Orr N; Cohen D; Lowell GH
Infect Immun; 1995 Jun; 63(6):2382-6. PubMed ID: 7768627
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
Orr N; Robin G; Cohen D; Arnon R; Lowell GH
Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.
Phalipon A; Kaufmann M; Michetti P; Cavaillon JM; Huerre M; Sansonetti P; Kraehenbuhl JP
J Exp Med; 1995 Sep; 182(3):769-78. PubMed ID: 7544397
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
5. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.
van de Verg LL; Mallett CP; Collins HH; Larsen T; Hammack C; Hale TL
Infect Immun; 1995 May; 63(5):1947-54. PubMed ID: 7729907
[TBL] [Abstract][Full Text] [Related]
6. Development of recombinant vaccine candidate molecule against Shigella infection.
Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
[TBL] [Abstract][Full Text] [Related]
7. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
8. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
mSphere; 2018; 3(2):. PubMed ID: 29600284
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
10. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y.
Ahmed ZU; Sarker MR; Sack DA
Vaccine; 1990 Apr; 8(2):153-8. PubMed ID: 2186582
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
[TBL] [Abstract][Full Text] [Related]
13. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
[TBL] [Abstract][Full Text] [Related]
14. Oral immunization of monkeys with polyvalent dysentery vaccine.
Dhikidze EK; Kavtaradze KN; Krilova RI; Rauss K; Kétyi I; Vertényi A
Acta Microbiol Acad Sci Hung; 1977; 24(1):7-12. PubMed ID: 412396
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
[TBL] [Abstract][Full Text] [Related]
16. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
[No Abstract] [Full Text] [Related]
17. Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.
Bernardini ML; Arondel J; Martini I; Aidara A; Sansonetti PJ
Infect Immun; 2001 Feb; 69(2):1072-83. PubMed ID: 11160004
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
Yagnik B; Sharma D; Padh H; Desai P
Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
20. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains.
Mel D; Gangarosa EJ; Radovanovic ML; Arsic BL; Litvinjenko S
Bull World Health Organ; 1971; 45(4):457-64. PubMed ID: 4948417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
